Related Experiment Video
Updated: Jul 19, 2026

Synthesis and Characterization of mRNA-Loaded Poly(Beta Aminoesters) Nanoparticles for Vaccination Purposes
Published on: August 13, 2021
Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases
Deborah H Fuller1, Peter Loudon, Connie Schmaljohn
1Department of Molecular Genetics and Biochemistry, University of Pittsburgh, School of Medicine, 260 Kappa Drive, PA 15238, USA. dfuller@pitt.edu
Abstract:
This review provides an overview of studies employing particle-mediated epidermal delivery (PMED) or the gene gun to administer DNA vaccines for infectious diseases in preclinical studies employing large animal models and in human clinical trials. It reviews the immunogenicity and protective efficacy of PMED DNA vaccines in nonhuman primates and swine and studies that have directly compared the effectiveness of PMED in these large animal models to existing licensed vaccines and intramuscular or intradermal delivery of DNA vaccines with a needle. Various clinical trials employing PMED have been completed and an overview of the immunogenicity, safety, and tolerability of this approach in humans is described. Finally, efforts currently in progress for commercial development of particle-mediated DNA vaccines are discussed.
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Preclinical Development: Overview
Vaccine Production

